Navigation Links
Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
Date:5/9/2011

CHICAGO, May 9, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the presentation of two abstracts at the 2011 Digestive Disease Week (DDW) conference highlighting additional analyses of data from Phase 3 trials of DIFICID™ (fidaxomicin), an investigational product for the treatment of Clostridium difficile infection (CDI).

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The first analysis aimed to identify risk factors associated with early recurrence (a relapse within the first two weeks after end of therapy) compared to late recurrence (a relapse during the third and fourth weeks after end of therapy). Data presented by Kathleen Mullane, PharmD, D.O., Associate Professor of Medicine at The University of Chicago Department of Medicine, demonstrated that the majority of recurrences occurred within two weeks of completing initial therapy (129/190, 67.9%). Treatment with DIFICID was associated with a 66% reduction of early recurrence compared with vancomycin (7.4% vs 19.3%, p<0.001), and late recurrence was the same in both treatment arms. In addition, elevated white blood cell counts and low albumin levels at the end of treatment and exposure to concomitant antibiotics during the follow-up period were associated with a higher risk of late recurrence.  The study titled "Risk of Recurrence and Time to Recurrence Following Treatment of Clostridium difficile Infection: Patient Characteristics and the Differential Effect of Fidaxomicin vs. Vancomycin," was presented on May 7.

"As many as 30 percent of patients initially treated for CDI will experience recurrent disease, or the persistence of CDI symptoms following initial treatment. This can cause significant loss of work productivity, keep people from their daily lives and, in some cases, cause repeated hospitalizations," said Dr. Mullane.
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rhythmia Medical Highlights Studies to be Presented at Heart Rhythm Society 2011 Annual Scientific Session
2. ConvaTec Supported Studies to be Presented at the 24th Annual Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS)
3. New Study Results Presented on Dexlansoprazole and Lansoprazole Effects on Plavix® (clopidogrel bisulfate)
4. Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections
5. REMEDIAL II Results on PLC Systems RenalGuard® to be Presented at ACC 2011s Late Breaking Clinical Trial Session
6. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
7. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
8. Advancements in GYN Oncology; Instrumentation and Techniques to be Presented by Nicholas C. Lambrou, M.D. of Miami
9. Urocidin™ Phase III Clinical Trial Results to be Presented at EAU and AUA Conferences
10. New England Patriots Offensive Line Wins Second Annual Madden Most Valuable Protectors Award Presented by Prilosec OTC®
11. New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... ALBANY, New York , July 11, 2014 /PRNewswire/ ... published by Transparency Market Research "Endoscopy Devices Market (Endoscopes, ... Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019" the ... billion in 2012 and is expected to grow at ... reach an estimated value of USD 36.9 billion in ...
(Date:7/11/2014)... 11, 2014  Veran Medical Technologies, a ... the positive, cost-effective final results for the ... The SPiNPerc endobronchial percutaneous biopsy study results ... to biopsy when a traditional bronchoscopic method ... experience positive financial outcomes when more can ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2
... , , MOUNTAIN VIEW, Calif. ... announced the initiation of a Phase I clinical trial ... autoimmune diseases.  CCX168 is a highly potent and very ... a component of the body,s complement system and a ...
... , Jan. 28 , Net Sales of $1.11 ... period (an increase of 2.5% constant currency) , Diluted ... from the prior year period, and $1.12 adjusted, an increase of 12.0% ... of $4.10 billion for the full year represent a decrease of 0.6% ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 2ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 3ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 4Zimmer Reports Fourth Quarter and 2009 Financial Results 2Zimmer Reports Fourth Quarter and 2009 Financial Results 3Zimmer Reports Fourth Quarter and 2009 Financial Results 4Zimmer Reports Fourth Quarter and 2009 Financial Results 5Zimmer Reports Fourth Quarter and 2009 Financial Results 6Zimmer Reports Fourth Quarter and 2009 Financial Results 7Zimmer Reports Fourth Quarter and 2009 Financial Results 8Zimmer Reports Fourth Quarter and 2009 Financial Results 9Zimmer Reports Fourth Quarter and 2009 Financial Results 10Zimmer Reports Fourth Quarter and 2009 Financial Results 11Zimmer Reports Fourth Quarter and 2009 Financial Results 12Zimmer Reports Fourth Quarter and 2009 Financial Results 13Zimmer Reports Fourth Quarter and 2009 Financial Results 14Zimmer Reports Fourth Quarter and 2009 Financial Results 15Zimmer Reports Fourth Quarter and 2009 Financial Results 16Zimmer Reports Fourth Quarter and 2009 Financial Results 17Zimmer Reports Fourth Quarter and 2009 Financial Results 18Zimmer Reports Fourth Quarter and 2009 Financial Results 19Zimmer Reports Fourth Quarter and 2009 Financial Results 20Zimmer Reports Fourth Quarter and 2009 Financial Results 21Zimmer Reports Fourth Quarter and 2009 Financial Results 22Zimmer Reports Fourth Quarter and 2009 Financial Results 23Zimmer Reports Fourth Quarter and 2009 Financial Results 24Zimmer Reports Fourth Quarter and 2009 Financial Results 25Zimmer Reports Fourth Quarter and 2009 Financial Results 26Zimmer Reports Fourth Quarter and 2009 Financial Results 27
(Date:7/13/2014)... According to a new market research report "Heterogeneous ... GPU, DSP, connectivity), Technology Node (45nm-5nm), Application (Consumer, ... and Analysis to 2014-2020", published by MarketsandMarkets, the ... expected to reach $61.70 Billion by 2020, growing ... 2020. , Browse 71 market data Tables with ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. Its ... beautiful. Recently, the company has announced its new selection ... more, all these outfits are available at discounted prices ... the supplier is now offering similar discounts for many ... has many other designs for sale, including flower girl ...
(Date:7/13/2014)... 2014 Wright & Schulte LLC has ... scheduled in July of 2015, in U.S. District Court, ... in the discovery process in the South Carolina ... presiding over the multidistrict litigation (MDL). The complaints pending ... individuals who allege that they took the statin medication ...
(Date:7/13/2014)... MI (PRWEB) July 13, 2014 If Dr. ... program he has just launched at http://www.HealthYourself101.com will ... visceral obesity. , Power has set out to provide ... ill effects that’s actually – dare we say it? – ... program,” says Power, “aims to engage the remote learner – ...
Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4
... as a surprise to politicians and rights leaders alike, mainly ... of girls in the 0-6 years category is coming down ... feticide and nothing else. The problem is that we are ... the guilty," said Health Minister P.K. Sreemathy Thursday while speaking ...
... Southwestern Medical Center, working with mice, have shown how ... decrease the fearful response associated with reliving a traumatic ... a mild electrical shock – mice in the study ... place where it happened, a condition that could be ...
... found a breakthrough in the treatment of breast cancer ... therapies.// ,According to Professor Miles Prince from Melbourne's ... emission tomography (PET) would probably change the way breast ... (PET) scans to monitor breast cancer patients to find ...
... in UK, 40% Of Adults Cannot Manage Without Cell ... Stoke-on-Trent, who had conducted the research//, claimed that certain ... their cell phones. In his study on how students ... of the behaviors displayed, closely resembled symptoms of ‘pathological ...
... Richards marks the rapid increase in esophageal cancer cases in the ... cancer.// Only 16 % or around 2,200, of the 14,000-esophageal cancer ... years. ,There has been a 6-fold annual rise in the ... to experts. Rise in obesity cases has been the major cause. ...
... can be effective in cluster headaches as well, researchers ... pain signals, Dr. Peter Goadsby, professor of clinical neurology ... not as common as migraines and affect one in ... In the final analysis 69 patients were included. These ...
Cached Medicine News:Health News:Pre-Clinical Study Suggests How Steroid Can Reverse Post-Traumatic Stress 2Health News:Pre-Clinical Study Suggests How Steroid Can Reverse Post-Traumatic Stress 3Health News:Aussie Doctors Claim Breakthrough in Breast Cancer Treatment 2Health News:Rise in Esophageal Cancer is emphasized by Richards’ deat 2
Microsect Curette with increased cutting edge and modified shaft, 10"....
Bone Curette, 160 mm...
Endocrette Endocervical Curette is a stainless-steel curette with closed blade....
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
Medicine Products: